We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Today, Jean-Marie Dupuy, President & Chief Executive Officer of Viropro Inc., "Viropro" or "the company" is proud to announce the signing of a Memorandum of Understanding (MOU) with BioChallenge, a privately-held pharmaceutical company operating in Tunis.
Athenagen, Inc., a privately held biopharmaceutical company, reported today that its lead compound, GTS-21, a novel, orally active alpha-7 nicotinic acetylcholine (nACh) receptor agonist, demonstrated cognition enhancement activity in a proof-of-concept study in patients with schizophrenia.
Intec Pharma, developer of the Accordion Pill(TM) gastric retention technology, announced today that it has entered into an agreement with two leading North American dosage form manufacturers in order to scale-up the company's manufacturing platform.
Aegerion Pharmaceuticals, Inc., a specialty pharmaceuticals company formed to focus on the development of compounds to treat cardiovascular and metabolic disease, today announced the closing of its $22.5 million Series A financing.
MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced that the Board of Directors has authorized to extend the previously announced stock option repurchase plan through December 31, 2006.
Almost 90 percent of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) were alive five years after they began receiving Gleevec (imatinib), drugmaker Novartis announced at the recent 2006 annual meeting of the American
Society of Clinical Oncology.
Rebuffed in his attempt to force a face-to-face meeting with an FDA special investigator, Sen. Chuck Grassley has charged the agency with covering up problems with its review of the antibiotic Ketek and threatened to hold hearings on the way regulators determine the safety of drugs.